Specifically , IRIS will test the effectiveness of pioglitazone , an insulin-sensitizing drug of the thiazolidinedione class , for reducing the risk for stroke and myocardial infarction ( MI ) among insulin resistant , nondiabetic patients with a recent ischemic stroke or TIA .